Generics And Price Cuts Hit Novartis’s Japan, Emerging Market Sales
This article was originally published in PharmAsia News
Executive Summary
Novartis, whose first quarter pharmaceuticals performance was weighed by Gleevec patent expiries, also suffered from weak sales in Japan and some emerging markets mainly due to impact from generics and price reductions.